Kane Biotech (CVE:KNE) Shares Up 33.3% – Here’s Why

Kane Biotech Inc. (CVE:KNE)’s stock price shot up 33.3% during mid-day trading on Monday . The stock traded as high as C$0.04 and last traded at C$0.04. 291,000 shares changed hands during trading, an increase of 65% from the average session volume of 175,845 shares. The stock had previously closed at C$0.03.

Kane Biotech Stock Performance

The company has a debt-to-equity ratio of -289.57, a quick ratio of 0.39 and a current ratio of 0.90. The stock has a fifty day simple moving average of C$0.03 and a two-hundred day simple moving average of C$0.04. The stock has a market capitalization of C$5.86 million, a price-to-earnings ratio of -0.44 and a beta of 1.04.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.